We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
67 result(s) found, displaying 31 to 40
-
YUFLYMA adalimumab 80 mg/0.8 mL solution for injection pre-filled syringe with safety guard (396991)
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab 80 mg/0.8 mL solution for injection pre-filled syringe with safety guard. -
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab 80 mg/0.8 mL solution for injection pre-filled syringe in auto injector pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab 80 mg/0.8 mL solution for injection pre-filled syringe.
-
Australian public assessment report (AusPar)Vegzelma (bevacizumab), in combination with fluoropyrimidine-based chemotherapy, has been approved for the treatment of metastatic colorectal cancer.
-
Prescription medicine registrationActive ingredients: Bevacizumab.
-
EMISIMA infliximab (rmc) 100mg Powder for Injection vial Cancelled under Section 30(1)(c) of the Act
Cancellation by sponsorRequested by Celltrion Healthcare Australia Pty Ltd -
Cancellation by sponsorRequested by Celltrion Healthcare Australia Pty Ltd
-
Cancellation by sponsorRequested by Celltrion Healthcare Australia Pty Ltd
-
Cancellation by sponsorRequested by Celltrion Healthcare Australia Pty Ltd
-
Cancellation by sponsorRequested by Celltrion Healthcare Australia Pty Ltd